Bekir Nihat Dogrul

Bekir Nihat Dogrul

Auto-generated profile, based on publicly available information

Bekir Nihat Dogrul

University of Rochester Medical Center

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2024 in Psychoradiology
Verified
Journal Article
Open access
PDF file
TPTanya Paul
Tanya Paul
JSJia Whei See
Jia Whei See
VVVetrivel Vijayakumar
Vetrivel Vijayakumar
TNTemiloluwa Njideaka-Kevin
Temiloluwa Njideaka-Kevin
HLHanyou Loh
Hanyou Loh
BDBekir Nihat Dogrul
Bekir Nihat Dogrul
Schizophrenia is a complex disorder characterized by multiple neurochemical abnormalities and structural changes in the brain. These abnormalities may begin before recognizable clinical symptoms appear and continue as a dynamic process throughout the illness. Recent advances in imaging techniques have significantly enriched our comprehension of these structural alterations, particularly focusing on gray and white matter irregularities and prefrontal, temporal, and cingulate cortex alterations. Some of the changes suggest treatment resistance to antipsychotic medications, while treatment nonadherence and relapses may further exacerbate structural abnormalities. This narrative review aims to discuss the literature about alterations and deficits within the brain, which could improve the understanding of schizophrenia and how to interpret neurostructural changes.

18 June 2024 in Journal of the Academy of Consultation-Liaison Psychiatry
Verified
Journal Article
Closed access
BDBekir Nihat Dogrul
Bekir Nihat Dogrul
CPClare Park
Clare Park

11 August 2026 in Journal of Nutritional Science
Verified
Journal Article
Open access
PDF file
BDBekir Nihat Dogrul
Bekir Nihat Dogrul
Lithium is a mainstay treatment in bipolar disorder and is used in various psychiatric conditions. Micro or trace doses have also been suggested to have potential neuropsychiatric effects. Dietary supplements containing lithium are available in the US, but no studies have evaluated their labelling regarding dosing, health claims, or precautionary practices. Products from the Dietary Supplement Label Database (DSLD) marketed between 2011 and 2025 were reviewed, with composition and dosing derived from declared labelling. Lithium amounts, mood-, cognitive-, and suicide-related claims, and precautions for pregnancy/breastfeeding, kidney, and antidepressant use were assessed, and associations with dosing were analysed using Mann–Whitney U tests with correction for multiple comparisons. Of 439 products, 99 met inclusion criteria. Forty-one percent were lithium-only, with reported elemental lithium ranging from trace amounts to 25 mg (median, 1.5 mg). Some elemental lithium amounts were comparable to the lowest manufactured doses of lithium carbonate. Lithium-only products contained higher elemental lithium than combination products ( p < 0.05), and lithium orotate was the predominant salt (52.5%). Products with mood-related claims had higher reported elemental lithium than those without (5 vs. 1 mg; p < 0.05), whereas no association was observed for cognitive claims. No products made suicide-related claims. Kidney- and antidepressant-related precautions were not associated with elemental lithium amounts, while products with pregnancy/breastfeeding precautions had higher reported content than those without (3.25 vs. 0.5 mg; p < 0.05). These findings highlight variability in dosing and labelling, with certain labelling features correlated with declared lithium amounts, possibly reflecting conventions in lithium use.

1 November 2021 in TURKISH MEDICAL STUDENT JOURNAL
Verified
Journal Article
Open access
IKİbRahim Kılıççalan
İbRahim Kılıççalan
BDBekir Nihat Doğrul
Bekir Nihat Doğrul
AEAbdulbaki Erkovan
Abdulbaki Erkovan
EAEkrem Samet Aşçı
Ekrem Samet Aşçı

20 March 2026 in Journal of Complementary and Integrative Medicine
Verified
Journal Article
Open access
PDF file
BDBekir Nihat Dogrul
Bekir Nihat Dogrul
IKIbrahim Kiliccalan
Ibrahim Kiliccalan
EAEkrem Samet Asci
Ekrem Samet Asci
Background: Crataegus azarolus (hawthorn) is a medicinal plant traditionally used for various health benefits and culinary reasons, although its psychiatric effects remain poorly studied. This study aimed to assess the volatile chemical composition and ionic profile of C. azarolus , and to integrate these findings with a targeted review of the literature to propose potential psychiatric implications. Methods: Methanolic extracts of dried flowers, leaves, and berries were analyzed by gas chromatography–mass spectrometry (GC–MS), with compounds identified using reference libraries. Ion chromatography (IC) with anion and cation columns was used to quantify inorganic ions, expressed as mg per 100 g dried material. Results: GC–MS tentatively identified 13 major compounds, including flavonoids, fatty acids, sterols, vitamin D derivatives, and digitoxin. Many of these constituents have been suggested having anti-inflammatory, antioxidant, anxiolytic, and antidepressant-like activities in preclinical studies. Among the compounds, the flavonoids quercetin and lucenin-2 were particularly notable due to their proposed roles in central nervous system function, neuroprotection and possible psychiatric effects. IC analysis additionally revealed the presence of various inorganic ions, although their overall concentrations were low. Conclusions: The biochemical complexity of C. azarolus highlights its potential relevance for mental health, yet direct preclinical and clinical evidence remains lacking. Future investigations are needed to clarify its psychiatric applications.

29 August 2026 in The Turkish Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
MAMeli̇ke Arslan
Meli̇ke Arslan
EBEdibe Gözde Başaran
Edibe Gözde Başaran
CÖCoşkun Fırat Özkeçeci
Coşkun Fırat Özkeçeci
BDBekir Nihat Doğrul
Bekir Nihat Doğrul
NBNecati Balamtekin
Necati Balamtekin
Background. Studies on gastroptosis and gastroparesis in children are limited. This prospective study aimed to evaluate the frequency of gastroptosis and gastroparesis and their association with duodenogastric reflux (DGR) and treatment-resistant dyspeptic symptoms in children. Methods. The study evaluated pediatric patients aged 2-18 years with dyspepsia who underwent upper gastrointestinal endoscopy between March 2020 and June 2022. Fluoroscopy and gastric emptying scintigraphy were performed in 88 patients (50 with DGR and 38 with treatment-resistant dyspepsia). Results. The mean age of the patients was 13.7±3.6 years, and 62 (70.5%) were girls. Gastroptosis was detected in 22 (25%) and gastroparesis in 24 (27%) of all 88 patients. Gastroptosis was present in 10 (20%) and gastroparesis in 20 (40%) of the 50 patients with DGR. Gastroptosis was present in 12 (32%) and gastroparesis in 4 (11%) of the 38 patients with treatment-resistant dyspepsia. Gastroparesis was more common in those with DGR (40%) than in those with treatment-resistant dyspepsia (11%) (p=0.09). Gastroptosis was also detected in 14 (58.3%) patients with gastroparesis. The median body mass index (BMI) z-score of those with gastroptosis was significantly lower than those without gastroptosis (p=0.002). Conclusions. Gastroptosis and gastroparesis were frequently identified in children with treatment-resistant dyspeptic symptoms or DGR. These conditions should be considered and investigated in this patient population.